OpenNashPodcasts

Person

Elif Korkmaz

1 episodes · 5 quoted claims

J.P. Morgan analysts expect the global market for GLP-1 drugs to exceed $100 billion over time.

“From the perspective of the pharma companies, we see the market for the GLP-1 category exceeding $100 billion over time globally.”

Making Sense (J.P. Morgan) · 0:00:04

Novo Nordisk released results of its SELECT cardiovascular outcomes study in August 2023, which coincided with a split in healthcare stock performance.

“especially around August when we had the select study from NOAA Nordisk looking at the cardiovascular outcomes”

Making Sense (J.P. Morgan) · 0:04:27

Medical device companies underperformed in 2023 amid fears about the impact of GLP-1 drugs.

“While companies on the medical device side of things, they really underperformed over these GLP-1 fears.”

Making Sense (J.P. Morgan) · 0:05:00

The SELECT study showed Wegovy reduced the risk of heart attacks, strokes and cardiovascular death by about 20%.

“not only helped people to lose weight, but also reduced their risk of suffering from heart attacks, strokes, cardiovascular deaths by 20%”

Making Sense (J.P. Morgan) · 0:05:00

J.P. Morgan's Chris Schott has estimated the U.S. obesity drug opportunity at approaching $50 billion by 2030.

“you previously said that you estimate obesity opportunity in the U.S. approaching 50 billion by 2030”

Making Sense (J.P. Morgan) · 0:08:01